Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712860 | 0.98 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL24468061 | 0.98 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL7259722 | 0.98 | TDP1 (0.64) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL766369 | 0.96 | TDP1 (0.59) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1115856 | 0.90 | CYP1A2 (0.54) | TDP1L3MBTL1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL6790333 | 0.89 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8862728 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL6777483 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL2604742 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL8862878 | 0.87 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | Madera Therapeutics, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612154-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024097436-A1 | REGULATORS OF PORPHYRIN AND INTERMEDIATES | Madera Therapeutics, LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-1869042-B1 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA SA (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-0816364-B1 | Reagents for lysergic acid diethylamide immunoassay | HOFFMANN LA ROCHE (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6476199-B1 | Reagents for lysergic acid diethylamide immunoassay | ROCHE DIAGNOSTICS CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-6063908-A | STABLE HAPTEN DERIVATIVES THAT ARE USEFUL FOR THE PREPARATION OF ANTIGENS, ANTIBODIES AND REAGENTS USED IN DETECTION OF DRUG ABUSE | ROCHE DIAGNOSTICS CORPORATION (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0816364-A1 | Reagents for lysergic acid diethylamide immunoassay | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| US-4560680-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4452791-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885L3MBTL1 1394/4885MAPT 2459/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885L3MBTL1 1394/4885MAPT 2459/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | TDP1 3079/4885L3MBTL1 2170/4885MAPT 4526/4885 |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | HSP90B1, HSP90AB2P, HSP90AB1 | TDP1 1837/4885L3MBTL1 4707/4885MAPT 767/4885 |
| US-12459945-B2 | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents | CLPP, PRCP, PREP | TDP1 1210/4885L3MBTL1 2708/4885MAPT 1873/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885L3MBTL1 1394/4885MAPT 2459/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885L3MBTL1 1394/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.